Results 81 to 90 of about 26,085 (201)

Exceptional Response of HER2‐Positive Breast Cancer to Osimertinib: A Case Report

open access: yesThoracic Cancer, Volume 17, Issue 16, August 2026.
An 83‐year‐old woman with synchronous EGFR L858R‐mutated lung adenocarcinoma and HER2‐positive breast cancer received osimertinib monotherapy for lung cancer without breast‐directed therapy. The breast tumor showed durable radiological and metabolic regression, with a Grade 3 therapeutic effect and HER2 amplification confirmed at postmortem biopsy ...
Hirotoshi Yasui   +10 more
wiley   +1 more source

TANC1::HTRA1 fusion in schwannomas

open access: yes
Brain Pathology, Volume 36, Issue 5, September 2026.
Ilay Caliskan   +3 more
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong   +28 more
wiley   +1 more source

Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment

open access: yesBMC Cancer
Triple-negative breast cancer (TNBC) is traditionally treated with systemic chemotherapy, often resulting in significant off-target toxicity. In this study, we assess the efficacy of intraductal chemotherapeutic delivery, aimed at reducing systemic side ...
Xinhong Wu   +7 more
doaj   +1 more source

Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience

open access: yesBJU International, Volume 138, Issue 2, Page 297-305, August 2026.
Objectives To report long‐term oncological outcomes of men with intermediate‐risk prostate cancer managed with active surveillance at a single centre. Subjects/Patients and Methods We retrospectively analysed a prospectively maintained Manitoba Prostate Centre active surveillance database.
Steven Lu   +3 more
wiley   +1 more source

Procedure‐specific morbidity and pathologic assessment after resection of small (≤20 mm) pancreatic neuroendocrine tumors

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Pancreatic neuroendocrine tumors (PanNETs) are increasingly detected, and the optimal extent of resection remains uncertain because perioperative burden and oncologic assessment may differ by procedure. Enucleation (EN) and central pancreatectomy (CP) are often grouped together as parenchyma‐sparing resections (PSRs) despite substantial ...
Aya Maekawa   +20 more
wiley   +1 more source

Issue Information

open access: yes
DEN Open, Volume 7, Issue 1, April 2027.
wiley   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

open access: yes
World Journal of Surgery, Volume 50, Issue 8, Page 2106-2115, August 2026.
S. George Barreto   +5 more
wiley   +1 more source

Intraductal Papillary Carcinoma

open access: yesThe Breast Journal, 2000
Jolinda, Mester   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy